Free Trial
→ A grave, grave error. (From Porter & Company) (Ad)
NASDAQ:PMCB

PharmaCyte Biotech 12/15/2023 Earnings Report

PharmaCyte Biotech logo
$1.07 +0.06 (+5.92%)
Closing price 03:59 PM Eastern
Extended Trading
$1.05 -0.02 (-2.15%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

PharmaCyte Biotech EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PharmaCyte Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PharmaCyte Biotech Announcement Details

Quarter
Date
12/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PharmaCyte Biotech's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

PharmaCyte Biotech Earnings Headlines

Comparing PharmaCyte Biotech (NASDAQ:PMCB) and Kiromic BioPharma (NASDAQ:KRBP)
May 18, 2025 | americanbankingnews.com
MyMD Pharmaceuticals Secures Strategic Investments
May 21, 2024 | businesswire.com
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
May 28, 2025 | Brownstone Research (Ad)
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 21, 2024 | businesswire.com
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
December 18, 2023 | msn.com
Companies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In Growth
December 15, 2023 | finance.yahoo.com
See More PharmaCyte Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PharmaCyte Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PharmaCyte Biotech and other key companies, straight to your email.

About PharmaCyte Biotech

PharmaCyte Biotech (NASDAQ:PMCB), a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View PharmaCyte Biotech Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles